Clinicoproteomics - A clinicoproteomic study of patients with cervical and endometrial malignant tumours
From 01-01-2005 to 31-12-2008
Description
The proteome, all proteins that are possibly present on a certain time point in a human tissue or serum, is characteristic for a specific examined sample and is influenced by the micro-environment and physio(patho)logical circumstances in which a tissue (or organism) finds itself. The presence of a malignant tumor in a human body will also influence the proteome present in the serum with over expression of some and under expression of other proteins. Especially the over expression of a certain protein can be used as a biological marker of the absence or presence of malignancy. It speaks for itself that the nature of a certain tumor (histopathologic type, tumor grade, resistance for certain types of chemotherapy or radiotherapy…) will also influence this proteome, causing a different protein profile caused by these changed circumstances. The subject of this research project is the profiling of proteomes of endometrial and cervical tumors by using serum and tissue samples of patients with one of these tumors. By comparing these protein profiles new biomarkers can be discovered for the prediction of the behavior of a tumor (e.g. local recurrence, pattern of metastases, chemo- or radioresistance…)Team
- Bart De Moor, Co-promoter
- Kristof Engelen, Team member
- Olivier Gevaert, Team member
Financing
Funding: FWO - Research Foundation - Flanders
Program/Grant Type: FWO Research Grant - FWO Research Grant
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.